Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 30.99% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $423.9 million, a 46.23% increase from a year earlier, with the FY2025 full-year figure at $426.7 million, down 6.77% from the prior year.
• Cash from Financing Activities slipped to $6.4 million in Q1 2026 per VRDN's latest filing, from $405.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $405.9 million in Q4 2025 and bottomed at $108000.0 in Q2 2024.
• The 5-year median for Cash from Financing Activities is $10.9 million (2025), against an average of $84.6 million.
• Across the five-year window, Cash from Financing Activities surged 15202.35% in 2022 and slumped 96.48% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $26.0 million in 2022, then soared by 664.75% to $198.9 million in 2023, then slumped by 82.14% to $35.5 million in 2024, then soared by 1042.63% to $405.9 million in 2025, then plunged by 98.43% to $6.4 million in 2026.
• Per Business Quant, the three latest VRDN Cash from Financing Activities figures stand at $6.4 million (Q1 2026), $405.9 million (Q4 2025), and $10.9 million (Q3 2025).